These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 25316870)

  • 21. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    PLoS One; 2015; 10(6):e0130123. PubMed ID: 26068928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
    Duintjer Tebbens RJ; Pallansch MA; Kim JH; Burns CC; Kew OM; Oberste MS; Diop OM; Wassilak SG; Cochi SL; Thompson KM
    Risk Anal; 2013 Apr; 33(4):680-702. PubMed ID: 23470192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.
    Thompson KM; Tebbens RJ
    Expert Rev Vaccines; 2012 Apr; 11(4):449-59. PubMed ID: 22551030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.
    Duintjer Tebbens RJ; Thompson KM
    Risk Anal; 2019 Feb; 39(2):389-401. PubMed ID: 30239026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating vaccine derived polio viruses and their impact on global polio eradication.
    Wagner BG; Earn DJ
    Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
    Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities.
    Khetsuriani N; Perehinets I; Nitzan D; Popovic D; Moran T; Allahverdiyeva V; Huseynov S; Gavrilin E; Slobodianyk L; Izhyk O; Sukhodolska A; Hegazi S; Bulavinova K; Platov S; O'Connor P
    Vaccine; 2017 Aug; 35(36):4769-4776. PubMed ID: 28528761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.
    Thompson KM; Duintjer Tebbens RJ
    Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
    Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
    PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Vaccine-Derived Polioviruses - Worldwide, January 2015-May 2016.
    Jorba J; Diop OM; Iber J; Sutter RW; Wassilak SG; Burns CC
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):763-9. PubMed ID: 27491079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.